Should You Buy Insulet Corp (PODD) Today? Analysis, Price Targets, and 2026 Outlook.
Analysis Updated At
2026/01/26
Insulet Corp (PODD) is not a strong buy at the moment for a beginner investor with a long-term horizon. While the company shows strong fundamentals and growth potential in the diabetes management market, the technical indicators and cautious market sentiment suggest waiting for a better entry point. The stock is currently trading below key support levels, and there are no strong proprietary trading signals to indicate immediate upside potential.
Technical Analysis
The technical indicators suggest a bearish trend. The MACD is negatively expanding, RSI is neutral at 24.285, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading below the pivot level of 280.727, with key support at 269.933 and resistance at 291.52. This indicates potential downside risk in the short term.
Analyst Ratings and Price Target Trends
Analysts maintain a positive outlook on Insulet, with most firms reiterating buy or outperform ratings. Recent price target adjustments reflect optimism, with targets ranging from $365 to $450. Analysts highlight the company's strong market position, growth potential in the diabetes management sector, and its ability to sustain multi-year growth despite competitive pressures.
Wall Street analysts forecast PODD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PODD is 375.83 USD with a low forecast of 316 USD and a high forecast of 450 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Wall Street analysts forecast PODD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PODD is 375.83 USD with a low forecast of 316 USD and a high forecast of 450 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Current: 258.200
Current: 258.200
